Living

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug

By Reuters Reuters
FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo
FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo Rachel Wisniewski Reuters

A European Medicines Agency committee said on Friday it has adopted a positive opinion of AstraZeneca's experimental breast cancer drug, camizestrant.

(Reporting by Ankita Bora in Bengaluru; Editing by Tasim Zahid)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published May 22, 2026 at 3:44 AM.

Get unlimited digital access
#ReadLocal

Try 1 month for $1

CLAIM OFFER